Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $183.4 million.

  • SAB Biotherapeutics' Liabilities and Shareholders Equity rose 24100.0% to $183.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.9 million, marking a year-over-year increase of 918.52%. This contributed to the annual value of $44.2 million for FY2024, which is 4734.95% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Liabilities and Shareholders Equity stood at $183.4 million for Q3 2025, which was up 24100.0% from $30.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Liabilities and Shareholders Equity's 5-year high stood at $183.4 million during Q3 2025, with a 5-year trough of $28.3 million in Q3 2023.
  • In the last 5 years, SAB Biotherapeutics' Liabilities and Shareholders Equity had a median value of $59.4 million in 2022 and averaged $70.4 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 5509.45% in 2022, then soared by 24100.0% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Liabilities and Shareholders Equity stood at $81.1 million in 2021, then crashed by 37.26% to $50.9 million in 2022, then soared by 64.9% to $83.9 million in 2023, then crashed by 47.35% to $44.2 million in 2024, then soared by 315.08% to $183.4 million in 2025.
  • Its last three reported values are $183.4 million in Q3 2025, $30.1 million for Q2 2025, and $38.1 million during Q1 2025.